Takeda Pharmaceutical Company Limited (TKPHF) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Tokyo, Japan. The current CEO is Christophe Weber.
TKPHF has IPO date of 2008-06-25, 49,281 full-time employees, listed on the Other OTC, a market capitalization of $54.53B.
Takeda Pharmaceutical Company Limited is a global pharmaceutical company headquartered in Tokyo, Japan, with operations across Japan, the United States, Europe, and other international markets. Founded in 1781, the company engages in the research, development, manufacture, and marketing of pharmaceutical products across five core therapeutic areas: gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Takeda markets numerous branded pharmaceutical products including Entyvio, Velcade, Adcetris, and Takhzyro, among others, and maintains an extensive network of collaborations, licensing agreements, and strategic alliances with leading research institutions and biotechnology companies worldwide to support its innovation pipeline.
